Trial NCT00655824

View at ClinicalTrials.gov 
Org. Study IDs: 111752
Secondary IDs: GEN413

Last trial update was posted on 2017-12-05

MeSH Interventions

Ofatumumab

MeSH Conditions

Arthritis Arthritis, Rheumatoid

Other Conditions


Stopping Reasons

The clinical development of intravenously administered ofatumumab in RA will no longer be pursued, so this study was prematurely terminated by the Sponsor.

Limitations And Caveats

Development of the IV route of ofatumumab (OFA) administration in RA will no longer be pursued. This study was prematurely terminated; OFA treatment was discontinued. Participants could complete only <=7 treatment courses and a follow-up evaluation.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID